Future Science Group
Browse
supplementary figure 1.pdf (1022.45 kB)

Supplementary figure 1.pdf: A Phase I trial of talazoparib in patients with advanced hematologic malignancies

Download (1022.45 kB)
figure
posted on 2021-10-23, 12:03 authored by Ajay K Gopal, Rakesh Popat, Ryan J Mattison, Tobias Menne, Adrian Bloor, Terry Gaymes, Asim Khwaja, Mark Juckett, Ying Chen, Matthew J Cotter, Ghulam J Mufti
Supplementary Figure 1. Dose linearity and proportionality in plasma following multiple doses of talazoparib.

Funding

This study was sponsored by Biomarin/Medivation, which was acquired by Pfizer Inc. in September 2016 (grant number not applicable).

History

Usage metrics

    International Journal of Hematologic Oncology

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC